Harbour BioMed has announced an update on the advancement of its global strategic collaboration with AstraZeneca to discover and develop next-generation biotherapeutics in oncology, including antibody-drug conjugates (ADCs) and T cell engagers.

Under the terms of the agreement, AstraZeneca will continue to nominate discovery programmes to Harbour BioMed each year over the next four years, reflecting the continued progress of the partnership, and will retain the option to license these programmes for further development. 

Harbour BioMed will receive option and option exercise fees, development and commercial milestone payments, plus tiered royalties on future net sales on such licensed programmes. The economic terms remain aligned with the financial framework established in March 2025.  

“Harbour BioMed has collaborated with AstraZeneca on multiple programs since 2022, and over time, the two parties have established a trusted and solid partnership. With our strong capabilities enabled by our proprietary antibody platforms, we are well positioned to support AstraZeneca in developing innovative biotherapeutics that can address significant unmet medical needs and improve patient outcomes globally,” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.